Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,809 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Complete response to an anti-programmed cell death 1 antibody following a combination therapy of an anti-programmed cell death ligand 1 antibody and a tyrosine kinase inhibitor for metastatic renal cell carcinoma.
Kurokawa M, Naito S, Kato T, Ushijima M, Yamagishi A, Sakurai T, Nishida H, Tsuchiya N. Kurokawa M, et al. Among authors: naito s. Asian J Urol. 2023 Jan;10(1):103-105. doi: 10.1016/j.ajur.2022.01.005. Epub 2022 Jul 16. Asian J Urol. 2023. PMID: 36721690 Free PMC article. No abstract available.
The lymphocyte-to-monocyte ratio as a significant inflammatory marker associated with survival of patients with metastatic renal cell carcinoma treated using nivolumab plus ipilimumab therapy.
Numakura K, Sekine Y, Osawa T, Naito S, Tokairin O, Muto Y, Sobu R, Kobayashi M, Sasagawa H, Yamamoto R, Nara T, Saito M, Narita S, Akashi H, Tsuchiya N, Shinohara N, Habuchi T. Numakura K, et al. Among authors: naito s. Int J Clin Oncol. 2024 May 26. doi: 10.1007/s10147-024-02538-8. Online ahead of print. Int J Clin Oncol. 2024. PMID: 38797782
Correction to: Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era - a multi‑institutional retrospective study.
Kato R, Naito S, Numakura K, Hatakeyama S, Koguchi T, Kojima T, Kawasaki Y, Kandori S, Kawamura S, Arai Y, Ito A, Nishiyama H, Kojima Y, Ohyama C, Habuchi T, Tsuchiya N, Obara W. Kato R, et al. Among authors: naito s. Int J Clin Oncol. 2023 May;28(5):726-727. doi: 10.1007/s10147-023-02331-z. Int J Clin Oncol. 2023. PMID: 37010622 Free PMC article. No abstract available.
Humoral and cellular immune response and the safety of third SARS-CoV-2 mRNA vaccine with longer interval after the second vaccination in kidney transplant recipients.
Takai S, Nishida H, Ito H, Fukuhara H, Nawano T, Narisawa T, Kanno H, Yagi M, Yamagishi A, Sakurai T, Naito S, Kato T, Morikane K, Tsuchiya N. Takai S, et al. Among authors: naito s. Front Immunol. 2022 Nov 30;13:1050211. doi: 10.3389/fimmu.2022.1050211. eCollection 2022. Front Immunol. 2022. PMID: 36532067 Free PMC article.
A randomized controlled trial of the size-adjustable cryoballoon vs conventional cryoballoon for paroxysmal atrial fibrillation: The CONTRAST-CRYO II trial rationale and design.
Kawamura I, Miyazaki S, Inamura Y, Nitta J, Kobori A, Nakamura K, Murakami M, Nakamura T, Inaba O, Sekiguchi Y, Asano S, Sasaki Y, Mizuno S, Naito S, Hirakawa A, Sasano T. Kawamura I, et al. Among authors: naito s. Heart Rhythm O2. 2024 Apr 12;5(5):301-306. doi: 10.1016/j.hroo.2024.04.006. eCollection 2024 May. Heart Rhythm O2. 2024. PMID: 38840770 Free PMC article.
1,809 results